FDA Approves Viridian’s TED Therapy

Rare Daily Staff

The U.S. Food and Drug Administration has approved Viridian Therapeutics’ Lumvoa for thyroid eye disease (TED), the company’s first commercial product.

The decision makes Lumvoa the first therapy labeled for use across both active and chronic TED, a distinction that could broaden its clinical utility in a disease where treatment options have historically been limited by stage of illness.

Thyroid eye disease is a rare autoimmune condition in which inflammation and tissue expansion behind the eye can cause symptoms such as eye bulging, double vision, pain, and, in severe cases, vision loss. For many patients, the condition is both physically and emotionally burdensome, affecting appearance, comfort, and the ability to work and carry out daily activities.

Lumvoa is a monoclonal antibody that targets the insulin‑like growth factor‑1 receptor (IGF‑1R), a validated pathway in TED. The drug is given as five intravenous infusions over 12 weeks, a shorter treatment course than some existing options. Lumvoa previously received Breakthrough Therapy designation and was reviewed under the FDA’s Priority Review program.

The approval is based on data from two phase 3 trials—THRIVE in active TED and THRIVE‑2 in chronic TED—which together represent one of the largest clinical programs conducted in this indication. Both studies met their primary and secondary endpoints, showing statistically significant improvements across key disease measures at 15 weeks.

Lumvoa also showed a rapid onset of effect. Reductions in proptosis were observed as early as three weeks. The therapy improved double vision (diplopia) as well, with complete resolution in some patients—an outcome that has been difficult to achieve consistently in prior TED studies.

The safety profile of Lumvoa is broadly in line with other IGF‑1R inhibitors. In clinical trials, infusion‑related reactions occurred in about 9 percent of patients and were generally manageable. Other important risks include high blood sugar (hyperglycemia), particularly in people with pre‑existing diabetes, worsening of inflammatory bowel disease, and hearing problems, which in some cases may be permanent. Common side effects included muscle spasms, headache, fatigue, diarrhea, and high blood pressure.

Viridian plans an immediate U.S. launch. The company has also introduced a patient support program, ViridianCares, intended to help with access to therapy, navigating insurance coverage, and providing financial assistance for eligible patients.

“TED can be physically painful and emotionally exhausting, and patients experience the disease as highly disruptive to their daily lives,” said Christine Gustafson, CEO of TED Community Organization. “Having a new treatment available could be very important for the many patients who are seeking help for thyroid eye disease.”